NV-1NCE
5.1.2023 15:31:41 CET | Business Wire | Press release
1NCE, a global IoT connectivity and software company, today announced the creation of its software business unit in conjunction with the Consumer Electronics Show launch of 1NCE OS – IoT software offering powerful developer tools and device control to make IoT even more accessible.
The software tools are an integral part of 1NCE’s Lifetime Flat service and are available complimentary to 1NCE customers.
1NCE OS is a foundational element of the company’s ambitious goal: to cement 1NCE’s standing as the preeminent destination for accessible IoT. It’s designed for easy integration of 1NCE’s connectivity and software features into IoT projects of any scale, for new and existing projects alike. Using 1NCE OS for device and cloud integration, customers can accelerate time-to-market for IoT projects by months. One of 1NCE’s core principles is that customer data isn’t to be monetized and used to sell additional services. Instead, 1NCE is transparent about turning data into tools that are included in the global lifetime flat rate.
Features available at launch:
- Device Authentication: The process of setting up a secure and automated solution usually requires a complicated and error-prone onboarding process. 1NCE OS makes it simple: customers just solder the secure SIM into their device just like any other hardware piece and that’s it – delivering better authentication and integration of uniquely identified devices into IoT projects.
- IoT Integrator: Reliably connecting devices to the cloud can be complex, but 1NCE’s managed protocol translation uses open industry standards (UDP, CoAP, LwM2M, AWS IoT Core, Webhooks) to give customers the free and full flexibility they demand.
- Device Inspector: The time-intensive and costly process of sending technicians into the field to monitor and service devices is significantly reduced using advanced remote access to device states and recent telemetry.
- Device Locator: Network based positioning helps users locate devices even without GPS.
- Energy Saver: The inherent challenges of battery-powered devices make power usage a high priority, and 1NCE’s optimized payload transmission can increase battery life by up to 50 percent.
Fredrik Stålbrand of Berg Insights said: “1NCE OS and 1NCE’s product roadmap look very compelling. Our view is that the IoT connectivity market will increasingly move towards digitalized sales and delivery. SIMs will be pre-installed in chipsets, while connectivity management is increasingly being controlled by SaaS applications. Customers expect simple, digital experiences throughout the product lifecycle. 1NCE is clearly at the forefront of this development.”
Ivo Rook, Chief Operating Officer at 1NCE: “1NCE flips the script for customers – we don’t monetize their data for a few extra dollars because our customers’ data is theirs and theirs alone. 1NCE’s move into software allows us to boost our customers’ ideas not just when they need connectivity, but from the outset of their projects and all the way through a device’s lifecycle. IoT connectivity and software for life for a single fee, and that’s it.”
Fifty percent of failed IoT projects falter in the pilot stage. For new IoT projects, 1NCE makes it easy to experiment early without major expenditures that can kill a project. Customers connect sensors across the globe at a fraction of the cost of the traditional price of network operators, and now with 1NCE OS, they gain access to software tools that accelerate time-to-market without vendor lock-in or paying for unnecessary features packaged into most IoT platforms. And for IoT projects that are already up and running, 1NCE’s combination of connectivity and software delivers trusted, production-grade solutions for continuous improvement and optimization.
The majority of IoT projects require multinational deployments, but few network operators have the capability to truly meet cross-border demands. The 1NCE Lifetime Flat service is industry-disruptive but simple: for $10/€10, customers can deploy, connect, and manage IoT sensors across the world for as little as a dollar per year per device. More than 10,000 customers worldwide already trust 1NCE with more than 15 million managed connections.
The company’s ability to deliver affordable and reliable IoT, and its rapid global expansion to 153 markets from 106 at the beginning of the year, helped 1NCE earn two prestigious awards recently: Honorable Mention on Fast Company’s list of the Next Big Things in Tech and top prize for the most outstanding use case in “innovative IoT” (in partnership with Flashnet) at Light Reading’s 18th annual Leading Lights.
More information about 1NCE OS can be found here and customers can get started with 1NCE at the company’s online shop and the AWS Marketplace. Customer support is available in 14 languages.
About 1NCE
1NCE is the only connectivity and software company providing IoT at a lifetime global flat rate. Our mission is to deliver true cross-border, future-proof IoT without uncertainty or hassle over the lifetime of a device. In 150+ countries, 1NCE turns connectivity into electricity ready for consumption – opening the world of IoT to innovators who will dramatically improve the environment, cities, healthcare, public safety, the supply chain and more. The company, founded in 2017 by CEO Alexander P. Sator together with Deutsche Telekom AG, is headquartered in Cologne, Germany and has 250+ staff across 20 countries. Learn more online and follow 1NCE on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
